Amarin Reports Year-End and Q4 2010 Results Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Reports Year-End and Q4 2010 Results
Amarin To Present At The 11th Annual BIO CEO & Investor Conference Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin To Present At The 11th Annual BIO CEO & Investor Conference
Amarin To Present At The Cowen & Company 29th Annual Health Care Conference Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin To Present At The Cowen & Company 29th Annual Health Care Conference
Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA
Amarin to Present at Lazard Capital Markets Annual Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin to Present at Lazard Capital Markets Annual Healthcare Conference
Amarin Corporation Appoints Kristine Peterson to Board of Directors Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Corporation Appoints Kristine Peterson to Board of Directors
Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin to Host Conference Call at 8:30 a.m. EST on November 29, 2010, to Discuss Top-Line Results of Phase 3 MARINE Study of AMR101 in Patients with Very High Triglycerides
Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial Submitted by amarin on Fri, 12/08/2017 - 04:48 Home Read more about Amarin Completes Patient Randomization in Phase 3 ANCHOR Trial
